CHAMPIONS ONCOLOGY, INC. reported third quarter of fiscal 2026, ended January 31, 2026 results: revenue $16.6 million, net income $279,000. Guidance reaffirmed.
“reference in such a filing. --- EX-99.1 (EX-99.1) --- NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Revenue of $16.6 Million Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year Hackensack, NJ – March 12 , 2026 – Champions Oncology, Inc.”
Brady Davis departed as President at CHAMPIONS ONCOLOGY, INC..
“Champions Oncology, Inc. deeply regrets to announce that its President, Mr. Brady Davis, passed away unexpectedly this week.”
Earnings Releases
CHAMPIONS ONCOLOGY, INC. reported first nine months of fiscal 2024 results: revenue $36.2 million.
“For the first nine months of fiscal 2024, revenue decreased 11.4% to $36.2 million compared to $40.8 million for the first nine months of fiscal 2023.”
Earnings Releases
CHAMPIONS ONCOLOGY, INC. reported third quarter ended January 31, 2024 results: revenue $12.0 million.
“Champions Oncology Reports Quarterly Revenue of $12.0 Million”
Earnings Releases
CHAMPIONS ONCOLOGY, INC. reported first six months of fiscal 2024 results: revenue $24.1 million.
“For the first six months of fiscal 2024, revenue decreased 13.9% to $24.1 million compared to $28.0 million for the first six months of fiscal 2023.”
Earnings Releases
CHAMPIONS ONCOLOGY, INC. reported its second quarter of fiscal 2024, ended October 31, 2023 results: revenue $11.6 million. Guidance lowered.
“Champions Oncology Reports Quarterly Revenue of $11.6 Million”
Shareholder Votes
CHAMPIONS ONCOLOGY, INC. shareholders approved Non-binding Advisory Resolution Relating to the Compensation of the Company’s Named Executive Officers at the 2023-10-19 meeting.
“3. Non-binding Advisory Resolution Relating to the Compensation of the Company’s Named Executive Officers. The proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as described in the Company's 2023 proxy statement, was approved by the following votes: Votes For Votes Against Abstain Broker Non-Vote 9,444,385 10,040 257,887 334,282”
Shareholder Votes
CHAMPIONS ONCOLOGY, INC. shareholders approved Ratification of Appointment of Independent Registered Accounting Firm. The appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024 at the 2023-10-19 meeting.
“2. Ratification of Appointment of Independent Registered Accounting Firm. The appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024, was ratified as follows: Votes For Votes Against Abstain 10,041,893 4,303 398”
Shareholder Votes
CHAMPIONS ONCOLOGY, INC. shareholders approved Election of Directors at the 2023-10-19 meeting.
“On October 19, 2023, Champions Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows: 1. Election of Directors. The seven director nominees named in the Company's 2023 proxy statement were elected to serve for a one-year term expiring at the 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified, based upon the following votes: Director Nominee Votes For Votes Withheld Broker Non-Vote Ronnie Morris, M.D. 8,988,585 723,727 334,282 Joel Ackerman 8,556,358 1,155,954 334,282 David Sidransky, M.D. 8,126,259 1,586,053 334,282 Daniel Mendelson 8,313,289 1,399,023 334,282 Robert Brainin 8,454,904 1,257,408 334,282 Scott R. Tobin 9,654,012 58,300 334,282 Philip Breitfeld, M.D. 9,658,058 54,254 334,282”
Brady Davis was appointed as President at CHAMPIONS ONCOLOGY, INC..
“On October 17, 2023, Champions Oncology, Inc. (the “Company”) announced the hiring and appointment of Brady Davis to serve as the Company’s President, effective as of October 9, 2023.”
Earnings Releases
CHAMPIONS ONCOLOGY, INC. reported financial results for first quarter of fiscal 2024 ended July 31, 2023.
“Total revenue for the first quarter of fiscal 2024 was $12.6 million compared to $13.7 million for the same period last year, a decrease of 8.6%.”
Earnings Releases
CHAMPIONS ONCOLOGY, INC. reported three months ended April 30, 2023 results: revenue $13.1 million.
“Total revenue for the fourth quarter of fiscal 2023 was $13.1 million, an increase of 2%, compared to $12.9 million for the same period last year.”
Earnings Releases
CHAMPIONS ONCOLOGY, INC. reported fiscal year ended April 30, 2023 results: revenue $53.9 million.
“Total revenue for fiscal year 2023 was $53.9 million, an increase of 10%, compared to $49.1 million for fiscal year 2022.”
Earnings Releases
CHAMPIONS ONCOLOGY, INC. reported third quarter of fiscal 2023, ended January 31, 2023 results: revenue $12.8 million.
“Champions Oncology Reports Quarterly Revenue of $12.8 Million”
Earnings Releases
CHAMPIONS ONCOLOGY, INC. reported second quarter of fiscal 2023, ended October 31, 2022 results: revenue $14.3 million. Guidance lowered.
“in such a filing. --- EX-99.1 (EX-99.1) --- NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Record Quarterly Revenue of $14.3 Million Hackensack, NJ – December 13 , 2022 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.